Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Przeglądasz jako GOŚĆ

Wyszukujesz frazę ""Zoledronic Acid"" wg kryterium: Temat


Tytuł :
Zoledronic Acid-Loaded β-TCP Inhibits Tumor Proliferation and Osteoclast Activation: Development of a Functional Bone Substitute for an Efficient Osteosarcoma Treatment.
Autorzy :
Kameda Y; Department of Applied Chemistry, School of Science and Technology, Meiji University, 1-1-1 Higashimita, Tama-ku, Kawasaki 214-8571, Kanagawa, Japan.
Aizawa M; Department of Applied Chemistry, School of Science and Technology, Meiji University, 1-1-1 Higashimita, Tama-ku, Kawasaki 214-8571, Kanagawa, Japan.
Sato T; Organization for the Strategic Coordination of Research and Intellectual Properties, Meiji University, 1-1-1 Higashimita, Tama-ku, Kawasaki 214-8571, Kanagawa, Japan.
Honda M; Department of Applied Chemistry, School of Science and Technology, Meiji University, 1-1-1 Higashimita, Tama-ku, Kawasaki 214-8571, Kanagawa, Japan.
Pokaż więcej
Źródło :
International journal of molecular sciences [Int J Mol Sci] 2021 Feb 14; Vol. 22 (4). Date of Electronic Publication: 2021 Feb 14.
Typ publikacji :
Journal Article
MeSH Terms :
Calcium Phosphates/*pharmacology
Cell Proliferation/*drug effects
Osteoclasts/*metabolism
Osteosarcoma/*metabolism
Zoledronic Acid/*pharmacology
Animals ; Bone Substitutes/chemistry ; Bone Substitutes/pharmacokinetics ; Bone Substitutes/pharmacology ; Calcium Phosphates/chemistry ; Calcium Phosphates/pharmacokinetics ; Cell Differentiation/drug effects ; Cell Line ; Cell Line, Tumor ; Cell Survival/drug effects ; Cells, Cultured ; Culture Media, Conditioned/pharmacology ; Drug Liberation ; Humans ; Male ; Mesenchymal Stem Cells/cytology ; Mesenchymal Stem Cells/metabolism ; Mice, Inbred C57BL ; Osteosarcoma/pathology ; Zoledronic Acid/chemistry ; Zoledronic Acid/pharmacokinetics
Czasopismo naukowe
Tytuł :
Symptomatic hypocalcemia following a single dose of zoledronic acid in a patient with bone metastases secondary to breast cancer.
Autorzy :
Sözel H; Department of Internal Medicine, Akdeniz University Medical School, Antalya, Turkey.
Yilmaz F; Department of Nephrology, Antalya Atatürk State Hospital, Antalya, Turkey.
Pokaż więcej
Źródło :
Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners [J Oncol Pharm Pract] 2021 Mar; Vol. 27 (2), pp. 494-497. Date of Electronic Publication: 2020 Jul 13.
Typ publikacji :
Case Reports; Journal Article
MeSH Terms :
Bone Density Conservation Agents/*adverse effects
Bone Neoplasms/*secondary
Breast Neoplasms/*pathology
Carcinoma, Ductal, Breast/*pathology
Hypocalcemia/*chemically induced
Zoledronic Acid/*adverse effects
Bone Density Conservation Agents/therapeutic use ; Bone Neoplasms/diagnostic imaging ; Breast Neoplasms/diagnostic imaging ; Carcinoma, Ductal, Breast/diagnostic imaging ; Female ; Humans ; Hypocalcemia/complications ; Hypophosphatemia/chemically induced ; Hypophosphatemia/drug therapy ; Magnetic Resonance Imaging ; Middle Aged ; Positron-Emission Tomography ; Vitamin D Deficiency/chemically induced ; Vitamin D Deficiency/drug therapy ; Zoledronic Acid/therapeutic use
Czasopismo naukowe
Tytuł :
Risk factors for skeletal-related events in non-small cell lung cancer patients treated with bone-modifying agents.
Autorzy :
Saito G; Department of Respirology, Graduate School of Medicine, Chiba University, Chiba, Japan.
Ebata T; Division of Epigenomics, National Cancer Center Research Institute, Tokyo, Japan.
Ishiwata T; Department of Respirology, Graduate School of Medicine, Chiba University, Chiba, Japan.
Iwasawa S; Department of Respirology, Graduate School of Medicine, Chiba University, Chiba, Japan. .
Yoshino I; Department of General Thoracic Surgery, Graduate School of Medicine, Chiba University, Chiba, Japan.
Takiguchi Y; Department of Medical Oncology, Graduate School of Medicine, Chiba University, Chiba, Japan.
Tatsumi K; Department of Respirology, Graduate School of Medicine, Chiba University, Chiba, Japan.
Pokaż więcej
Źródło :
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer [Support Care Cancer] 2021 Jul; Vol. 29 (7), pp. 4081-4088. Date of Electronic Publication: 2021 Jan 06.
Typ publikacji :
Journal Article
MeSH Terms :
Bone Density Conservation Agents/*adverse effects
Bone Density Conservation Agents/*therapeutic use
Carcinoma, Non-Small-Cell Lung/*drug therapy
Denosumab/*adverse effects
Lung Neoplasms/*drug therapy
Zoledronic Acid/*adverse effects
Adult ; Aged ; Aged, 80 and over ; Bone Neoplasms/secondary ; Bone and Bones/pathology ; Carcinoma, Non-Small-Cell Lung/pathology ; Denosumab/therapeutic use ; Female ; Fractures, Spontaneous/complications ; Humans ; Hypercalcemia/complications ; Lung Neoplasms/pathology ; Male ; Middle Aged ; Proportional Hazards Models ; Risk Factors ; Spinal Cord Compression/complications ; Zoledronic Acid/therapeutic use
Czasopismo naukowe
Tytuł :
Atrial fibrillation in patients treated with intravenous zoledronic or pamidronic acid: a pharmacoepidemiological study.
Autorzy :
Pijnenburg L; Department of Rheumatology, Hôpitaux Universitaires de Strasbourg, Strasbourg University, Strasbourg, France.
Salem JE; Department of Pharmacology, AP-HP, Pitié-Salpêtrière Hospital, CIC-1421, Regional Pharmacovigilance Center INSERM, Sorbonne Universités, Paris, France.
Lebrun-Vignes B; Department of Pharmacology, AP-HP, Pitié-Salpêtrière Hospital, CIC-1421, Regional Pharmacovigilance Center INSERM, Sorbonne Universités, Paris, France.
Sibilia J; Department of Rheumatology, Hôpitaux Universitaires de Strasbourg, Strasbourg University, Strasbourg, France.
Javier RM; Department of Rheumatology, Hôpitaux Universitaires de Strasbourg, Strasbourg University, Strasbourg, France.
Arnaud L; Department of Rheumatology, Hôpitaux Universitaires de Strasbourg, Strasbourg University, Strasbourg, France.
Pokaż więcej
Źródło :
European journal of endocrinology [Eur J Endocrinol] 2021 Mar; Vol. 184 (3), pp. 437-444.
Typ publikacji :
Journal Article; Systematic Review
MeSH Terms :
Atrial Fibrillation/*chemically induced
Atrial Fibrillation/*epidemiology
Drug-Related Side Effects and Adverse Reactions/*epidemiology
Pamidronate/*adverse effects
Zoledronic Acid/*adverse effects
Administration, Intravenous ; Aged ; Aged, 80 and over ; Databases, Factual ; Europe/epidemiology ; Female ; Humans ; Male ; North America/epidemiology ; Pamidronate/administration & dosage ; Pharmacoepidemiology ; Pharmacovigilance ; World Health Organization ; Zoledronic Acid/administration & dosage
Czasopismo naukowe
Tytuł :
Effects of bisphosphonates on osteoporosis: Focus on zoledronate.
Autorzy :
Oryan A; Department of Pathology, School of Veterinary Medicine, Shiraz University, Shiraz, Iran. Electronic address: .
Sahvieh S; Department of Pathology, School of Veterinary Medicine, Shiraz University, Shiraz, Iran.
Pokaż więcej
Źródło :
Life sciences [Life Sci] 2021 Jan 01; Vol. 264, pp. 118681. Date of Electronic Publication: 2020 Oct 29.
Typ publikacji :
Journal Article; Review
MeSH Terms :
Bone Density/*drug effects
Bone Density Conservation Agents/*therapeutic use
Diphosphonates/*therapeutic use
Osteoporosis/*drug therapy
Zoledronic Acid/*therapeutic use
Bone Density/physiology ; Bone Density Conservation Agents/pharmacology ; Bone Remodeling/drug effects ; Bone Remodeling/physiology ; Bone Resorption/drug therapy ; Bone Resorption/metabolism ; Bone Resorption/pathology ; Diphosphonates/pharmacology ; Humans ; Osteoporosis/metabolism ; Osteoporosis/pathology ; Treatment Outcome ; Zoledronic Acid/pharmacology
Czasopismo naukowe
Tytuł :
A phase II study of palliative radiotherapy combined with zoledronic acid hydrate for metastatic bone tumour from renal cell carcinoma.
Autorzy :
Harada H; Division of Radiation Therapy, Radiation and Proton Therapy Center, Shizuoka Cancer Center, Shizuoka, Japan.
Shikama N; Department of Radiation Oncology, Graduate School of Medicine, Juntendo University, Tokyo, Japan.
Wada H; Department of Radiation Oncology, Southern TOHOKU Proton Therapy Center, Fukushima, Japan.
Uchida N; Department of Radiation Oncology, Tottori University, Tottori, Japan.
Nozaki M; Dokkyo Medical Unversity, Saitama Medical Center, Saitama, Japan.
Hayakawa K; Department of Radiology and Radiation Oncology, Kitasato University School of Medicine, Kanagawa, Japan.; Department of Radiation Oncology, NHO Disaster Medical Center, Tokyo, Japan.
Yamada K; Department of Radiation Oncology, Seirei Mikatahara General Hospital, Shizuoka, Japan.
Nagakura H; Department of Radiology, KKR Sapporo Medical Center, Hokkaido, Japan.
Ogawa H; Division of Radiation Therapy, Radiation and Proton Therapy Center, Shizuoka Cancer Center, Shizuoka, Japan.
Miyazawa K; Department of Radiation Oncology, Showa General Hospital, Tokyo, Japan.
Katagiri H; Division of Orthopedic Oncology, Shizuoka Cancer Center, Shizuoka, Japan.
Nakamura N; Department of Radiation Oncology, St. Marianna University School of Medicine, Kanagawa, Japan.
Pokaż więcej
Źródło :
Japanese journal of clinical oncology [Jpn J Clin Oncol] 2021 Jan 01; Vol. 51 (1), pp. 100-105.
Typ publikacji :
Clinical Trial, Phase II; Journal Article; Multicenter Study
MeSH Terms :
Palliative Care*
Bone Neoplasms/*drug therapy
Bone Neoplasms/*radiotherapy
Carcinoma, Renal Cell/*drug therapy
Carcinoma, Renal Cell/*radiotherapy
Kidney Neoplasms/*drug therapy
Kidney Neoplasms/*radiotherapy
Zoledronic Acid/*therapeutic use
Aged ; Aged, 80 and over ; Bone Neoplasms/pathology ; Female ; Follow-Up Studies ; Humans ; Kaplan-Meier Estimate ; Kidney Neoplasms/pathology ; Male ; Middle Aged ; Neoplasm Recurrence, Local/drug therapy ; Treatment Outcome ; Zoledronic Acid/pharmacology
Czasopismo naukowe
Tytuł :
Various pathways of zoledronic acid against osteoclasts and bone cancer metastasis: a brief review.
Autorzy :
Wang L; Department of General Surgery, Fuling Central Hospital of Chongqing City, Chongqing, China.
Fang D; Department of General Surgery, Fuling Central Hospital of Chongqing City, Chongqing, China.
Xu J; Department of General Surgery, Fuling Central Hospital of Chongqing City, Chongqing, China.
Luo R; Department of Ultrasound, Fuling Central Hospital of Chongqing City, Chongqing, 408300, China. .
Pokaż więcej
Źródło :
BMC cancer [BMC Cancer] 2020 Nov 03; Vol. 20 (1), pp. 1059. Date of Electronic Publication: 2020 Nov 03.
Typ publikacji :
Journal Article; Review
MeSH Terms :
Bone Neoplasms/*drug therapy
Bone Neoplasms/*secondary
Osteoclasts/*cytology
Zoledronic Acid/*pharmacology
Animals ; Bone Neoplasms/metabolism ; Cell Differentiation/drug effects ; Cell Movement/drug effects ; Cell Proliferation/drug effects ; Cell Survival/drug effects ; Gene Expression Regulation, Neoplastic/drug effects ; Humans ; Osteoclasts/drug effects ; Osteoclasts/metabolism ; Reactive Oxygen Species/metabolism ; Signal Transduction/drug effects ; Zoledronic Acid/therapeutic use
Czasopismo naukowe
Tytuł :
Zoledronic acid sequential therapy could avoid disadvantages due to the discontinuation of less than 3-year denosumab treatment.
Autorzy :
Kondo H; Department of Orthopaedic Surgery, Obase Hospital, 1598 Aratsu Kanda-machi, Miyako-gun, 800-0344, Fukuoka, Japan. .
Okimoto N; Okimoto Clinic, Kure, Japan.
Yoshioka T; Department of Orthopaedic Surgery, Shimura Hospital, Hiroshima, Japan.
Akahoshi S; Department of Orthopaedic Surgery, Obase Hospital, 1598 Aratsu Kanda-machi, Miyako-gun, 800-0344, Fukuoka, Japan.
Fuse Y; Department of Orthopaedic Surgery, Saka Midorii Hospital, Hiroshima, Japan.
Ogawa T; Department of Orthopaedic Surgery, Kaisei General Hospital, Sakaide, Japan.
Okazaki Y; Department of Orthopaedic Surgery, Tobata General Hospital, Kitakyushu, Japan.
Katae Y; Katae Orthopaedic and Rheumatology Clinic, Kitakyushu, Japan.
Tsukamoto M; Department of Orthopaedic Surgery, School of Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan.
Yamanaka Y; Department of Orthopaedic Surgery, School of Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan.
Kawasaki M; Department of Orthopaedic Surgery, School of Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan.
Sakai A; Department of Orthopaedic Surgery, School of Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan.
Pokaż więcej
Źródło :
Journal of bone and mineral metabolism [J Bone Miner Metab] 2020 Nov; Vol. 38 (6), pp. 894-902. Date of Electronic Publication: 2020 Jul 12.
Typ publikacji :
Journal Article; Multicenter Study; Observational Study
MeSH Terms :
Withholding Treatment*
Denosumab/*therapeutic use
Zoledronic Acid/*therapeutic use
Aged ; Aged, 80 and over ; Biomarkers/blood ; Bone Density/drug effects ; Bone Density Conservation Agents/adverse effects ; Bone Density Conservation Agents/therapeutic use ; Bone Remodeling/drug effects ; Denosumab/adverse effects ; Female ; Fractures, Bone/blood ; Fractures, Bone/epidemiology ; Fractures, Bone/physiopathology ; Humans ; Male ; Middle Aged ; Osteoporosis/blood ; Retrospective Studies ; Tartrate-Resistant Acid Phosphatase/blood ; Zoledronic Acid/adverse effects
Czasopismo naukowe
Tytuł :
A single dose of zoledronate preserves bone mineral density for up to 2 years after a second course of romosozumab.
Autorzy :
McClung MR; Oregon Osteoporosis Center, 2881 NW Cumberland Road, Portland, OR 97210, USA. .; Mary MacKillop Institute for Health Research, Australian Catholic University, Melbourne, VIC, Australia. .
Bolognese MA; Bethesda Health Research Center, Bethesda, MD, USA.
Brown JP; Laval University and CHU de Québec (CHUL) Research Centre, Québec City, QC, Canada.
Reginster JY; University of Liège, Liège, Belgium.; King Saud University, Riyadh, Kingdom of Saudi Arabia.
Langdahl BL; Aarhus University Hospital, Aarhus, Denmark.
Maddox J; Amgen Inc., Thousand Oaks, CA, USA.
Shi Y; Amgen Inc., Thousand Oaks, CA, USA.
Rojeski M; Amgen Inc., Thousand Oaks, CA, USA.
Meisner PD; UCB Pharma, Brussels, Belgium.
Grauer A; Amgen Inc., Thousand Oaks, CA, USA.
Pokaż więcej
Źródło :
Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA [Osteoporos Int] 2020 Nov; Vol. 31 (11), pp. 2231-2241. Date of Electronic Publication: 2020 Jul 04.
Typ publikacji :
Clinical Trial, Phase II; Journal Article
MeSH Terms :
Antibodies, Monoclonal*/administration & dosage
Bone Density Conservation Agents*/administration & dosage
Osteoporosis, Postmenopausal*/drug therapy
Zoledronic Acid*/administration & dosage
Aged ; Bone Density ; Female ; Humans ; Middle Aged
Czasopismo naukowe
Tytuł :
Zoledronate and SPIO dual-targeting nanoparticles loaded with ICG for photothermal therapy of breast cancer tibial metastasis.
Autorzy :
Jiang Z; Department of Orthopedics, Xiangya Hospital, Central South University, Changsha, 410008, Hunan, China.
Li J; Department of Orthopedics, Xiangya Hospital, Central South University, Changsha, 410008, Hunan, China.
Chen S; Departmen of Ultrasound Diagnosis, The Second Xiangya Hospital, Central South University, Changsha, 410011, Hunan, China.
Guo Q; Department of Orthopedics, Xiangya Hospital, Central South University, Changsha, 410008, Hunan, China.
Jing Z; Department of Orthopedics, Xiangya Hospital, Central South University, Changsha, 410008, Hunan, China.
Huang B; Departmen of Ultrasound Diagnosis, The Second Xiangya Hospital, Central South University, Changsha, 410011, Hunan, China.
Pan Y; Department of Orthopedics, Xiangya Hospital, Central South University, Changsha, 410008, Hunan, China.
Wang L; Department of Orthopedics, Xiangya Hospital, Central South University, Changsha, 410008, Hunan, China. .
Hu Y; Department of Orthopedics, Xiangya Hospital, Central South University, Changsha, 410008, Hunan, China. .
Pokaż więcej
Źródło :
Scientific reports [Sci Rep] 2020 Aug 13; Vol. 10 (1), pp. 13675. Date of Electronic Publication: 2020 Aug 13.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Bone Neoplasms/*secondary
Bone Neoplasms/*therapy
Indocyanine Green/*adverse effects
Photothermal Therapy/*methods
Tibia/*pathology
Zoledronic Acid/*administration & dosage
Animals ; Breast Neoplasms/pathology ; Cell Line, Tumor ; Female ; Humans ; Indocyanine Green/chemistry ; Indocyanine Green/pharmacology ; Magnetic Iron Oxide Nanoparticles/chemistry ; Mice ; Polylactic Acid-Polyglycolic Acid Copolymer/chemistry ; RAW 264.7 Cells ; Treatment Outcome ; Zoledronic Acid/chemistry ; Zoledronic Acid/pharmacology
Czasopismo naukowe
Tytuł :
Denosumab Versus Zoledronic Acid in the Prevention of Skeletal-related Events in Vulnerable Cancer Patients: A Meta-analysis of Randomized, Controlled Trials.
Autorzy :
Chen C; Department of Pharmacy, Peking University First Hospital, Beijing, People's Republic of China; Department of Pharmacy Administration and Clinical Pharmacy, School of Pharmaceutical Sciences, Peking University Health Science Center, Beijing, People's Republic of China.
Li R; Department of Pharmacy, Peking University First Hospital, Beijing, People's Republic of China; Department of Pharmacy Administration and Clinical Pharmacy, School of Pharmaceutical Sciences, Peking University Health Science Center, Beijing, People's Republic of China.
Yang T; Department of Pharmacy, Peking University First Hospital, Beijing, People's Republic of China.
Ma L; Department of Pharmacy, Peking University First Hospital, Beijing, People's Republic of China.
Zhou S; Department of Pharmacy, Peking University First Hospital, Beijing, People's Republic of China; Department of Pharmacy Administration and Clinical Pharmacy, School of Pharmaceutical Sciences, Peking University Health Science Center, Beijing, People's Republic of China.
Li M; Department of Pharmacy, Peking University First Hospital, Beijing, People's Republic of China; Department of Pharmacy Administration and Clinical Pharmacy, School of Pharmaceutical Sciences, Peking University Health Science Center, Beijing, People's Republic of China.
Zhou Y; Department of Pharmacy, Peking University First Hospital, Beijing, People's Republic of China; Department of Pharmacy Administration and Clinical Pharmacy, School of Pharmaceutical Sciences, Peking University Health Science Center, Beijing, People's Republic of China. Electronic address: .
Cui Y; Department of Pharmacy, Peking University First Hospital, Beijing, People's Republic of China; Department of Pharmacy Administration and Clinical Pharmacy, School of Pharmaceutical Sciences, Peking University Health Science Center, Beijing, People's Republic of China. Electronic address: .
Pokaż więcej
Źródło :
Clinical therapeutics [Clin Ther] 2020 Aug; Vol. 42 (8), pp. 1494-1507.e1. Date of Electronic Publication: 2020 Jul 24.
Typ publikacji :
Journal Article; Meta-Analysis; Research Support, Non-U.S. Gov't; Systematic Review
MeSH Terms :
Bone Density Conservation Agents/*therapeutic use
Bone Neoplasms/*drug therapy
Denosumab/*therapeutic use
Multiple Myeloma/*drug therapy
Zoledronic Acid/*therapeutic use
Bone Density Conservation Agents/adverse effects ; Bone Neoplasms/secondary ; Denosumab/adverse effects ; Humans ; Randomized Controlled Trials as Topic ; Zoledronic Acid/adverse effects
Czasopismo naukowe
Tytuł :
The efficacy and safety of zoledronic acid and strontium-89 in treating non-small cell lung cancer: a systematic review and meta-analysis of randomized controlled trials.
Autorzy :
Hu Z; Department of Respiratory Medicine, The First College of Clinical Medicine Science, Three Gorges University, No. 183 Yiling Road, Yichang, 443003, People's Republic of China. .; Department of Respiratory Medicine, Yichang Central People's Hospital, Yichang, China. .
Tian Y; Clinical Research Center, Three Gorges University, No. 183 Yiling Road, Yichang, 443003, People's Republic of China.
Li W; Department of Respiratory Medicine, The First College of Clinical Medicine Science, Three Gorges University, No. 183 Yiling Road, Yichang, 443003, People's Republic of China.; Department of Respiratory Medicine, Yichang Central People's Hospital, Yichang, China.
Ruan Y; Department of Respiratory Medicine, The First College of Clinical Medicine Science, Three Gorges University, No. 183 Yiling Road, Yichang, 443003, People's Republic of China.; Department of Respiratory Medicine, Yichang Central People's Hospital, Yichang, China.
Zeng F; Department of Respiratory Medicine, The First College of Clinical Medicine Science, Three Gorges University, No. 183 Yiling Road, Yichang, 443003, People's Republic of China.; Department of Respiratory Medicine, Yichang Central People's Hospital, Yichang, China.
Pokaż więcej
Źródło :
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer [Support Care Cancer] 2020 Jul; Vol. 28 (7), pp. 3291-3301. Date of Electronic Publication: 2019 Nov 21.
Typ publikacji :
Journal Article; Meta-Analysis; Systematic Review
MeSH Terms :
Bone Density Conservation Agents/*therapeutic use
Carcinoma, Non-Small-Cell Lung/*drug therapy
Strontium Radioisotopes/*therapeutic use
Zoledronic Acid/*therapeutic use
Bone Density Conservation Agents/pharmacology ; Carcinoma, Non-Small-Cell Lung/mortality ; Humans ; Randomized Controlled Trials as Topic ; Strontium Radioisotopes/pharmacology ; Survival Analysis ; Zoledronic Acid/pharmacology
Czasopismo naukowe
Tytuł :
Longitudinal in vivo monitoring of callus remodeling in BMP-7- and Zoledronate-treated fractures.
Autorzy :
Mathavan N; Department of Biomedical Engineering, Lund University, Lund, Sweden.
Raina DB; Department of Orthopaedics, Clinical Sciences, Lund University and Skåne University Hospital, Lund, Sweden.
Tägil M; Department of Orthopaedics, Clinical Sciences, Lund University and Skåne University Hospital, Lund, Sweden.
Isaksson H; Department of Biomedical Engineering, Lund University, Lund, Sweden.; Department of Orthopaedics, Clinical Sciences, Lund University and Skåne University Hospital, Lund, Sweden.
Pokaż więcej
Źródło :
Journal of orthopaedic research : official publication of the Orthopaedic Research Society [J Orthop Res] 2020 Sep; Vol. 38 (9), pp. 1905-1913. Date of Electronic Publication: 2020 Mar 01.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Bone Density Conservation Agents/*therapeutic use
Bone Morphogenetic Protein 7/*therapeutic use
Fracture Healing/*drug effects
Fractures, Open/*drug therapy
Zoledronic Acid/*therapeutic use
Animals ; Bone Density Conservation Agents/pharmacology ; Bone Morphogenetic Protein 7/pharmacology ; Drug Evaluation, Preclinical ; Fractures, Open/diagnostic imaging ; Male ; Rats, Sprague-Dawley ; X-Ray Microtomography ; Zoledronic Acid/pharmacology
Czasopismo naukowe
Tytuł :
Effects of once-yearly zoledronic acid on bone density and incident vertebral fractures in nonmetastatic castration-sensitive prostate cancer patients with osteoporosis.
Autorzy :
Watanabe, Daisuke (AUTHOR)
Kimura, Takahiro (AUTHOR)
Watanabe, Ken (AUTHOR)
Takano, Hiromitsu (AUTHOR)
Uehara, Yuko (AUTHOR)
Minowa, Tadaaki (AUTHOR)
Yamashita, Akemi (AUTHOR)
Yoshikawa, Seiichiro (AUTHOR)
Mizushima, Akio (AUTHOR)
Pokaż więcej
Źródło :
BMC Cancer. 4/16/2021, Vol. 21 Issue 1, p1-7. 7p.
Czasopismo naukowe
Tytuł :
The effect of high concentration of zoledronic acid on tooth induced movement and its repercussion on root, periodontal ligament and alveolar bone tissues in rats.
Autorzy :
de Sousa, Fátima Regina Nunes
de Sousa Ferreira, Vanessa Costa
da Silva Martins, Conceição
Dantas, Hugo Victor
de Sousa, Frederico Barbosa
Girão-Carmona, Virgínia Cláudia Carneiro
Goes, Paula
de Castro Brito, Gerly Anne
de Carvalho Leitão, Renata Ferreira
Pokaż więcej
Źródło :
Scientific Reports. 4/7/2021, Vol. 11 Issue 1, p1-13. 13p.
Czasopismo naukowe
Tytuł :
Zoledronic acid reduces the rate of clinical fractures after surgical repair of a hip fracture regardless of the Pretreatment bone mineral density.
Autorzy :
Lyles KW; Duke University School of Medicine, Durham, NC, USA. .; GRECC, VA Medical Center, Durham, NC, USA. .
Bauer DC; University of California, San Francisco, San Francisco, CA, USA.; California Pacific Medical Center, San Francisco, CA, USA.
Colon-Emeric CS; Duke University School of Medicine, Durham, NC, USA.; GRECC, VA Medical Center, Durham, NC, USA.
Pieper CF; Duke University School of Medicine, Durham, NC, USA.
Cummings SR; University of California, San Francisco, San Francisco, CA, USA.; California Pacific Medical Center, San Francisco, CA, USA.
Black DM; University of California, San Francisco, San Francisco, CA, USA.; California Pacific Medical Center, San Francisco, CA, USA.
Pokaż więcej
Źródło :
Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA [Osteoporos Int] 2021 Jun; Vol. 32 (6), pp. 1217-1219. Date of Electronic Publication: 2021 Apr 27.
Typ publikacji :
Journal Article
MeSH Terms :
Bone Density Conservation Agents*/therapeutic use
Hip Fractures*/prevention & control
Hip Fractures*/surgery
Bone Density ; Femur Neck/surgery ; Humans ; Zoledronic Acid/therapeutic use
Czasopismo naukowe
Tytuł :
Sonic hedgehog signaling is associated with resistance to zoledronic acid in CD133high/CD44high prostate cancer stem cells.
Autorzy :
Acikgoz E; Department of Histology and Embryology, Faculty of Medicine, Van Yuzuncu Yil University, Van, 65080, Turkey. .
Mukhtarova G; Department of Medical Genetics, Ege University Medical School, İzmir, 35080, Turkey.; Department of Basic Oncology, Graduate School of Health Sciences, Ege University, Izmir, 35080, Turkey.
Alpay A; Department of Health Bioinformatics, Graduate School of Health Sciences, Ege University, Izmir, 35080, Turkey.
Avci CB; Department of Medical Biology, Faculty of Medicine, Ege University, Izmir, 35080, Turkey.
Bagca BG; Department of Medical Biology, Faculty of Medicine, Ege University, Izmir, 35080, Turkey.
Oktem G; Department of Histology and Embryology, Faculty of Medicine, Ege University, Izmir, 35080, Turkey.; Department of Stem Cell, Institute of Health Science, Ege University, Izmir, 35080, Turkey.
Pokaż więcej
Źródło :
Molecular biology reports [Mol Biol Rep] 2021 Apr; Vol. 48 (4), pp. 3567-3578. Date of Electronic Publication: 2021 May 04.
Typ publikacji :
Journal Article
MeSH Terms :
Drug Resistance, Neoplasm*
Hedgehog Proteins/*metabolism
Neoplastic Stem Cells/*metabolism
Prostatic Neoplasms/*metabolism
AC133 Antigen/genetics ; AC133 Antigen/metabolism ; Antineoplastic Agents/toxicity ; Bone Density Conservation Agents/toxicity ; Cell Line, Tumor ; Hedgehog Proteins/genetics ; Humans ; Hyaluronan Receptors/genetics ; Hyaluronan Receptors/metabolism ; Male ; Signal Transduction ; Zoledronic Acid/toxicity
Czasopismo naukowe
Tytuł :
Addition of dexamethasone to manage acute phase responses following initial zoledronic acid infusion.
Autorzy :
Chen FP; Keelung Osteoporosis Prevention and Treatment Center, Chang Gung Memorial Hospital, Keelung, 204, Taiwan. .; Department of Obstetrics and Gynecology, Keelung Chang Gung Memorial Hospital, 222 Mai-Chin Rd., Keelung, 204, Taiwan. .; Department of Medicine, College of Medicine, Chang Gung University, Kwei-Shan, Taoyuan, 259, Taiwan. .
Fu TS; Keelung Osteoporosis Prevention and Treatment Center, Chang Gung Memorial Hospital, Keelung, 204, Taiwan.; Department of Orthopaedic Surgery, Keelung Chang Gung Memorial Hospital, Keelung, 204, Taiwan.
Lin YC; Keelung Osteoporosis Prevention and Treatment Center, Chang Gung Memorial Hospital, Keelung, 204, Taiwan.; Department of Radiology, Keelung Chang Gung Memorial Hospital, Keelung, 204, Taiwan.
Lin YJ; Research Service Center for Health Information, Chang Gung University, Tao-Yuan, 259, Taiwan.
Pokaż więcej
Źródło :
Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA [Osteoporos Int] 2021 Apr; Vol. 32 (4), pp. 663-670. Date of Electronic Publication: 2020 Oct 28.
Typ publikacji :
Journal Article
MeSH Terms :
Bone Density Conservation Agents*/adverse effects
Osteoporosis, Postmenopausal*
Acute-Phase Reaction/chemically induced ; Dexamethasone/adverse effects ; Diphosphonates/adverse effects ; Female ; Humans ; Imidazoles/adverse effects ; Zoledronic Acid
Czasopismo naukowe
Tytuł :
Immune Modulation Properties of Zoledronic Acid on TcRγδ T-Lymphocytes After TcRαβ/CD19-Depleted Haploidentical Stem Cell Transplantation: An analysis on 46 Pediatric Patients Affected by Acute Leukemia.
Autorzy :
Merli P; Department of Pediatric Hematology and Oncology and of Cell and Gene Therapy, Scientific Institute for Research and Healthcare (IRCCS), Bambino Gesù Childrens' Hospital, Rome, Italy.
Algeri M; Department of Pediatric Hematology and Oncology and of Cell and Gene Therapy, Scientific Institute for Research and Healthcare (IRCCS), Bambino Gesù Childrens' Hospital, Rome, Italy.
Galaverna F; Department of Pediatric Hematology and Oncology and of Cell and Gene Therapy, Scientific Institute for Research and Healthcare (IRCCS), Bambino Gesù Childrens' Hospital, Rome, Italy.
Milano GM; Department of Pediatric Hematology and Oncology and of Cell and Gene Therapy, Scientific Institute for Research and Healthcare (IRCCS), Bambino Gesù Childrens' Hospital, Rome, Italy.
Bertaina V; Department of Pediatric Hematology and Oncology and of Cell and Gene Therapy, Scientific Institute for Research and Healthcare (IRCCS), Bambino Gesù Childrens' Hospital, Rome, Italy.
Biagini S; Department of Pediatric Hematology and Oncology and of Cell and Gene Therapy, Scientific Institute for Research and Healthcare (IRCCS), Bambino Gesù Childrens' Hospital, Rome, Italy.
Girolami E; Department of Pediatric Hematology and Oncology and of Cell and Gene Therapy, Scientific Institute for Research and Healthcare (IRCCS), Bambino Gesù Childrens' Hospital, Rome, Italy.
Palumbo G; Department of Pediatric Hematology and Oncology and of Cell and Gene Therapy, Scientific Institute for Research and Healthcare (IRCCS), Bambino Gesù Childrens' Hospital, Rome, Italy.
Sinibaldi M; Department of Pediatric Hematology and Oncology and of Cell and Gene Therapy, Scientific Institute for Research and Healthcare (IRCCS), Bambino Gesù Childrens' Hospital, Rome, Italy.
Becilli M; Department of Pediatric Hematology and Oncology and of Cell and Gene Therapy, Scientific Institute for Research and Healthcare (IRCCS), Bambino Gesù Childrens' Hospital, Rome, Italy.
Leone G; Transfusion Unit, Department of Laboratories, Scientific Institute for Research and Healthcare (IRCCS), Bambino Gesù Childrens' Hospital, Rome, Italy.
Boccieri E; Department of Pediatric Hematology and Oncology and of Cell and Gene Therapy, Scientific Institute for Research and Healthcare (IRCCS), Bambino Gesù Childrens' Hospital, Rome, Italy.
Grapulin L; Department of Radiology and Radiotherapy, Sapienza University, Rome, Italy.
Gaspari S; Department of Pediatric Hematology and Oncology and of Cell and Gene Therapy, Scientific Institute for Research and Healthcare (IRCCS), Bambino Gesù Childrens' Hospital, Rome, Italy.
Airoldi I; Stem Cell Laboratory and Cell Therapy Center, Giannina Gaslini Institute (IRCCS), Genoa, Italy.
Strocchio L; Department of Pediatric Hematology and Oncology and of Cell and Gene Therapy, Scientific Institute for Research and Healthcare (IRCCS), Bambino Gesù Childrens' Hospital, Rome, Italy.
Pagliara D; Department of Pediatric Hematology and Oncology and of Cell and Gene Therapy, Scientific Institute for Research and Healthcare (IRCCS), Bambino Gesù Childrens' Hospital, Rome, Italy.
Locatelli F; Department of Pediatric Hematology and Oncology and of Cell and Gene Therapy, Scientific Institute for Research and Healthcare (IRCCS), Bambino Gesù Childrens' Hospital, Rome, Italy.; Sapienza, University of Rome, Rome, Italy.
Pokaż więcej
Źródło :
Frontiers in immunology [Front Immunol] 2020 May 12; Vol. 11, pp. 699. Date of Electronic Publication: 2020 May 12 (Print Publication: 2020).
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Antigens, CD19/*immunology
Hematopoietic Stem Cell Transplantation/*methods
Immunologic Factors/*administration & dosage
Leukemia, Myeloid, Acute/*therapy
Lymphocyte Depletion/*methods
Receptors, Antigen, T-Cell, alpha-beta/*immunology
Receptors, Antigen, T-Cell, gamma-delta/*immunology
T-Lymphocytes/*drug effects
Transplantation Conditioning/*methods
Transplantation, Haploidentical/*methods
Zoledronic Acid/*administration & dosage
Adolescent ; B-Lymphocytes/immunology ; Child ; Child, Preschool ; Cohort Studies ; Disease-Free Survival ; Feasibility Studies ; Female ; Graft vs Host Disease/immunology ; Graft vs Host Disease/prevention & control ; Humans ; Immunologic Factors/adverse effects ; Infant ; Male ; T-Lymphocytes/immunology ; Transplantation, Homologous/methods ; Young Adult ; Zoledronic Acid/adverse effects
Czasopismo naukowe
Tytuł :
Cardiovascular and skeletal safety of zoledronic acid in osteoporosis observational, matched cohort study using Danish and Swedish health registries.
Autorzy :
Rubin KH; OPEN, Department of Clinical Research, University of Southern Denmark and Odense University Hospital, Odense, Denmark.
Möller S; OPEN, Department of Clinical Research, University of Southern Denmark and Odense University Hospital, Odense, Denmark.
Choudhury A; Novartis Healthcare Pvt. Ltd., Hyderabad, India.
Zorina O; Novartis Pharma AG, Basel, Switzerland.
Kalsekar S; Novartis Healthcare Pvt. Ltd., Hyderabad, India.
Eriksen EF; Department of Endocrinology, Rikshospitalet and University of Oslo, Oslo, Norway.
Andersen M; Centre for Pharmacoepidemiology, Clinical Epidemiology Unit, Karolinska Institutet Stockholm, Sweden; Department of Drug Design and Pharmacology, University of Copenhagen, Denmark.
Abrahamsen B; OPEN, Department of Clinical Research, University of Southern Denmark and Odense University Hospital, Odense, Denmark; Department of Medicine, Holbæk, Hospital, Denmark. Electronic address: .
Pokaż więcej
Źródło :
Bone [Bone] 2020 May; Vol. 134, pp. 115296. Date of Electronic Publication: 2020 Feb 22.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Bone Density Conservation Agents*/adverse effects
Osteoporosis*/drug therapy
Zoledronic Acid*/adverse effects
Cohort Studies ; Denmark ; Humans ; Registries ; Risk Factors ; Sweden/epidemiology
Czasopismo naukowe

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies